NASDAQ NMS - GLOBAL MARKET · ERNA
+9.51% · +$0.4300 · Vol 71.1K
Market closed · last close 4:00 PM ET · price as of 19:48:07 ET
Ernexa Therapeutics Inc

Ernexa Therapeutics Inc

Biotechnology
$4.95
Card
Relationship Map

Veridion Score

BETALOW CONF · 5/6 factorsMethodology
Sentiment absence reason unknown
ERNA
Ernexa Therapeutics Inc
Fri Aug 21 · last completed session · Markets closed · resumes Mon 9:30 ET
NEUTRAL

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

46/ 100
Veridion Score
NEUTRAL · LOW confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 5/6 factors with data · Fri Aug 21 · last completed session · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is ERNA moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading ERNA catalysts
About Ernexa Therapeutics Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2021
Employees
5
Country
US

Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$4.53
Day high
$5.20
Day low
$4.53
Previous close
$4.52
52W high
$47.00
-89.47% from high
52W low
$3.28
4% of range
Market cap
$5.7M
EPS
$-10.6500
Beta
1.71
Shares out
1.2M
Volume
71.1K
0.08× rel vol
Avg volume
939.2K
VWAP
$4.89
Price history computed in-house
1W
+21.92%
1M
+25.95%
3M
-56.69%
1Y
-86.80%
YTD
-83.50%
SMA 50 $5.27 · below
SMA 200 $14.85 · below
52W position 4%

ERNA overview

Veridion Score
46
Registered · 2026-08-21
5 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around ERNA.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading ERNA Form 4 filings
Public disclosures

Congress activity in ERNA

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for ERNA in the cached public ledger.

Federal contracts

ERNA contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for ERNA in this window.
Lobbying spend

ERNA lobbying filings, year to date.

Registered lobbying filings matched to Ernexa Therapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for ERNA in this window.
Loading news for ERNA
Analyst ratings
Sovereign unlock shows live analyst consensus for ERNA.
Options
Sovereign unlock shows live options positioning for ERNA.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.